Eli Lilly and Company, LLYThe legal complaints name Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide as defendants. Federal regulators issued an unambiguous warning in June, declaring that distribution of retatrutide alongside other unauthorized GLP-1 compounds violates federal law and cannot be legally compounded under current regulations. The corporation is simultaneously urging social networking platforms, online marketplaces, financial transaction services, credit institutions, and logistics companies to implement stricter policies against merchants peddling unauthorized retatrutide formulations. This dramatic uptick in confiscations illustrates the accelerating expansion of underground markets for unauthorized GLP-1 therapeutics, fueled by widespread consumer appetite for weight management solutions. Lilly’s enforcement efforts against unauthorized retatrutide merchants predates the recent litigation.